Cited by 250Dementia and Cognitive Impairment ResearchTreatment of Major DepressionAlzheimer's disease research and treatments

Sertraline for the treatment of depression in Alzheimer disease

Open access
Rosenberg, Paul B., Martin, Barbara K., Frangakis, Constantine, Mintzer, Jacobo E., Weintraub, Daniel, Porsteinsson, Anton P., Schneider, Lon S., Rabins, Peter V. +4 more·2010·The American Journal of Geriatric Psychiatry

Abstract

Objective Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled "Depression in Alzheimer's Disease-2" to assess the efficacy and tolerability of sertraline for depression in AD.Methods One hundred thirty-one participants from five U.S. medical centers with mild-to-moderate AD (Mini-Mental State Examination scores 10-26) and depression of AD were randomized to double-blinded treatment with sertraline (N = 67) or placebo (N = 64), with a target dosage of 100 mg daily. Efficacy was assessed using logistic regressions and mixed effects models in an intention-to-treat analysis with imputation of missing data. Principal outcome measures were modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC), change in Cornell Scale for Depression in Dementia (CSDD) scores, and remission defined by both mADCS-CGIC score <or=2 and CSDD score <or=6.Results mADCS-CGIC ratings (odd ratio [OR = 1.01], 95% confidence interval [CI]: 0.52-1.97, p = 0.98), CSDD scores (median difference at 12 weeks 1.2, 95% CI: 1.65-4.05, p = 0.41), and remission at 12 weeks of follow-up (OR = 2.06, 95% CI: 0.84-5.04, p = 0.11) did not differ between sertraline (N = 67) and placebo (N = 64). Sertraline-treated patients experienced more adverse events, most notably gastrointestinal and respiratory, than placebo-treated patients.Conclusion Sertraline did not demonstrate efficacy for the treatment depression symptoms in patients with AD. In addition, its use was associated with an increased incidence of adverse events. Thus, selective serotonin reuptake inhibitors may be of limited value for treating depression in patients with AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jgp.0b013e3181c796eb

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The method of drug discovery by re-purposing FDA drugs is inherently limited especially in terms of interpreting null results.

    “While this method of drug discovery has the attractive feature of studying drugs with generally well-characterized safety profiles, it is inherently limited especially in terms of interpreting null results (Rosenberg et al., 2010).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [21]Garre-Olmo J Lopez-Pousa S Vilalta-Franch J Carer's burden and depressive symptoms in patients with alzheimer s disease. state after twelve months Rev Neurol 2002 34 601 607 12080507

Cited by

Sorted by citations

Authors
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., Lyketsos, C. G., & Drye, L. T.
Affiliations
  • Johns Hopkins University (US)
  • Medical University of South Carolina (US)
  • Mental Illness Research, Education and Clinical Centers (US)
  • University of Rochester Medicine (US)
  • University of Southern California (US)
Corresponding author
Rosenberg, Paul B.
Venue
The American Journal of Geriatric Psychiatry
Publisher
Elsevier BV
Published
2010-02
Volume
18
Issue
2
Pages
136-145
ISSN
1064-7481 (ISSN-L)
OpenAlex
W1983522355
Cited by
250
References
36
Citations by year
2026: 7 · 2025: 10 · 2024: 14 · 2023: 5 · 2022: 14 · 2021: 8 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 14 · 2016: 11 · 2015: 21 · 2014: 21 · 2013: 24 · 2012: 24
FWCI
19.46
Type
journal article
Language
en
Open access
Locations
  • American Journal of Geriatric Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5u01mh068014-05, 5u01mh066176-05, 5u01mh066174-05, 5u01mh066177-05, 5u01mh066175-05)
  • National Institute on Aging (K08AG029157, P50AG005142, P50AG005146)
  • National Institute of Mental Health (U01 MH068014, U01 MH066174, 1U01MH066175, 1U01MH068014, U01MH066177, 1U01MH066177, 1U01MH066176, U01 MH066175, 1U01MH066174, U01 MH066176, U01MH066136)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
sertraline, Alzheimer's disease, depression, selective serotonin reuptake inhibitors, antidepressant efficacy, adverse events, depression remission, Cornell Scale for Depression in Dementia, mild to moderate dementia
MeSH terms
Assessment of Medication Adherence, Aged, Alzheimer Disease, Depression, Double-Blind Method, Female, Humans, Male, Patient Dropouts, Placebos, Treatment Outcome, Drug Monitoring, Selective Serotonin Reuptake Inhibitors, Sertraline, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review